XBIO (Xenetic Biosciences) ROIC %: -615.95% (As of Mar. 2026)


XBIO Xenetic Biosciences Inc XBIO
84 GF Score
Price $2.77
GF Value $4.19
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences ROIC %?

Xenetic Biosciences XBIO -5.78% 84 ROIC % is -615.95% as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 84/100 and a GF Value™ of $4.19 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Xenetic Biosciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -615.95%.

As of today (2026-07-02), Xenetic Biosciences's WACC % is 11.57%. Xenetic Biosciences's ROIC % is -743.48% (calculated using TTM income statement data). Xenetic Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Xenetic Biosciences  (NAS:XBIO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Xenetic Biosciences's WACC % is 11.57%. Xenetic Biosciences's ROIC % is -743.48% (calculated using TTM income statement data). Xenetic Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Xenetic Biosciences ROIC % Related Terms


Xenetic Biosciences ROIC % Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences ROIC % Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -571.27 -593.20 -415.46 -594.63 -827.74

Xenetic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,140.09 -922.29 0.00 -737.28 -615.95

XBIO vs ACXP, SILO, GOVX: ROIC % Comparison

For the Biotechnology subindustry, Xenetic Biosciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's ROIC % falls into.


XBIO
84GF Score
Xenetic Biosciences Inc XBIO
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences ROIC % Calculation

Xenetic Biosciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-2.835 * ( 1 - 0% )/( (0.347 + 0.338)/ 2 )
=-2.835/0.3425
=-827.74 %

where

Xenetic Biosciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-2.008 * ( 1 - 0% )/( (0.338 + 0.314)/ 2 )
=-2.008/0.326
=-615.95 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -615.95% mean?
Xenetic Biosciences (XBIO) has a ROIC % of -615.95% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' ROIC % too high?
Xenetic Biosciences' current ROIC % is -615.95%. Overall, Xenetic Biosciences has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' ROIC % compare to ACXP and SILO?
Xenetic Biosciences' ROIC % of -615.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current ROIC % is -615.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.19, compared to a current price of $2.77 — trading 33.9% below its estimated fair value. The current ROIC % is -615.95%. Xenetic Biosciences' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current ROIC % is -615.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.77 is trading 33.9% below its estimated GF Value™ of $4.19. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • ROIC %: -615.95%
  • GF Value™: $4.19 vs. price of $2.77 (33.9% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
84GF Score

Get the complete analysis for XBIO

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$4.19
GF Value